-
Mashup Score: 3
The algorithm looks for changes in the tiny blood vessels feeding the back of the eye and the complex patterns linked to broader cardiovascular disease.
Source: FierceBiotechCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 3
The algorithm looks for changes in the tiny blood vessels feeding the back of the eye and the complex patterns linked to broader cardiovascular disease.
Source: FierceBiotechCategories: General Medicine News, Latest HeadlinesTweet-
Researchers in the U.K. say they trained an artificial intelligence system to predict patients' heart attack risk using retinal scans. By @ConorHale via @FierceBiotech. https://t.co/QHRp0qxdwx
-
-
Mashup Score: 0CAR-NK cell therapy extends survival in pancreatic cancer mouse model, CytoImmune plans 2022 trial - 2 year(s) ago
Using natural killer cells from umbilical cords, City of Hope showed that a CAR-NK cell therapy was able to boost length of survival in a mouse model of pancreatic cancer using a freezing and thawing method. CytoImmune Therapeutics is slated to test the therapy in humans later this year.
Source: FierceBiotechCategories: Hem/Oncs, Latest HeadlinesTweet-
Answers in #pancreaticcancer CAR-NK cell therapy extends survival in pancreatic cancer mouse model, @CytoImmune plans 2022 trial. Can't wait @coughlin582 !!! https://t.co/xEE75whdei
-
-
Mashup Score: 2
The algorithm looks for changes in the tiny blood vessels feeding the back of the eye and the complex patterns linked to broader cardiovascular disease.
Source: FierceBiotechCategories: Expert Picks, Latest HeadlinesTweet-
Using the eyes as a window, AI predicts annual heart attack risk from retinal scans | FierceBiotech. #kahnchronicle https://t.co/BtMCWylw3e
-
-
Mashup Score: 0Fierce JPM Week: Johnson & Johnson's JLABS—Taming the beast, while letting it roam the world - 2 year(s) ago
JLABS has grown into a massive organization that spans the globe and is helping big ideas from small beginnings get off the ground.
Source: FierceBiotechCategories: Future of Medicine, Latest HeadlinesTweet-
Fierce JPM Week: Johnson & Johnson's JLABS—Taming the beast, while letting it roam the world https://t.co/uvDshqI16t @JLABS @melindarichter #pharma #digitalhealth
-
-
Mashup Score: 4Merck's chronic cough med gets a nay from FDA, potentially clearing first-to-market path for Bellus - 2 year(s) ago
The FDA rejected Merck’s chronic cough treatment, potentially setting up more breathing room for competitor Bellus Health in a first-to-market battle.
Source: FierceBiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
Merck's chronic cough med gets a nay from FDA, potentially clearing first-to-market path for Bellus https://t.co/zCc3ZjpXVq
-
-
Mashup Score: 4Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia - 2 year(s) ago
Sanofi is getting deeper into AI-driven R&D. After working with AI drug discovery shop Exscientia for five years, Sanofi has significantly expanded its relationship, putting up $100 million and $5.2 billion on the backend for the chance to work on up to 15 small molecules across oncology and immunology.
Source: FierceBiotechCategories: Future of Medicine, Latest HeadlinesTweet-
Sanofi makes AI play, putting up $100M and billions in biobucks to form broad deal with Exscientia https://t.co/x8ZJddsKat #AI #digitalhealth #pharma @SanofiUS @exscientiaAI
-
-
Mashup Score: 0Not just for a pandemic: Decentralized clinical trials pay off financially, study finds - 2 year(s) ago
Decentralized clinical trials rode a massive wave during the COVID-19 pandemic as sites, academic centers and hospitals changed the way they conduct their research. A new study from Tufts says there are “substantial” potential benefits to these types of clinical studies, including time and cost savings.
Source: FierceBiotechCategories: Future of Medicine, Latest HeadlinesTweet-
"What we’re doing today, is showing that financially there is return on investment when you deploy DCTs,” highlighted @medableinc's CSO to @FierceBiotech when they discussed the outcomes of our new research initiative with @TuftsCSDD. Read here: https://t.co/OXcrd9EYUW
-
-
Mashup Score: 6Revivicor's genetically modified pig heart is first successfully transplanted in human patient - 2 year(s) ago
Once as improbable an idea as seeing pigs fly, the xenotransplantation of organs from animals to humans is becoming an increasingly viable option as the science of genetic editing improves and organ donor waitlists lengthen.
Source: FierceBiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
The pig heart #xenotransplant came from United Therapeudics subsidiary Revivicor, founded by Martine Rothblatt @Skybiome. The pig herd had undergone #CRISPR editing. 4 of the pig’s genes were inactivated, & 6 human genes were inserted into its genome. https://t.co/KTs3FNzuBn
-
-
Mashup Score: 4Not just for a pandemic: Decentralized clinical trials pay off financially, study finds - 2 year(s) ago
Decentralized clinical trials rode a massive wave during the COVID-19 pandemic as sites, academic centers and hospitals changed the way they conduct their research. A new study from Tufts says there are “substantial” potential benefits to these types of clinical studies, including time and cost savings.
Source: FierceBiotechCategories: Healthcare Professionals, Latest HeadlinesTweet-
Not just for a pandemic: Decentralized clinical trials pay off financially, study finds: @medableinc @DTRAorg #DCT #decentralizedtrials https://t.co/B3NS9c8OkM
-
Can AI predict heart attack risk from retinal scans? https://t.co/fLoK49zbCd